[BLPH] Bellerophon Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 24.26 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.54 Change: -0.03 (-5.03%)
Ext. hours: Change: 0 (0%)

chart BLPH

Refresh chart

Strongest Trends Summary For BLPH

BLPH is in the long-term down -80% below S&P in 3 years and down -96% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding13.48 M EPS-1.66 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-0.75
P/E To EPS Growth P/S P/BV0.39 Price/Cash Per Share
Price/Free Cash Flow ROA-34.16% ROE-41.16% ROI
Current Ratio5.75 Quick Ratio Long Term Debt/Equity Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities54.91 M Cash From Investing Activities Cash From Operating Activities-8.79 M Gross Profit
Net Profit-12.91 M Operating Profit-14.09 M Total Assets75.18 M Total Current Assets73.57 M
Total Current Liabilities12.79 M Total Debt Total Liabilities12.79 M Total Revenue
Technical Data
High 52 week2.53 Low 52 week0.56 Last close0.68 Last change4.31%
RSI56.62 Average true range0.05 Beta1.2 Volume449 K
Simple moving average 20 days4.64% Simple moving average 50 days7.13% Simple moving average 200 days-7.99%
Performance Data
Performance Week4.31% Performance Month5.94% Performance Quart4.15% Performance Half4.95%
Performance Year12.79% Performance Year-to-date-15.4% Volatility daily3.83% Volatility weekly8.57%
Volatility monthly17.57% Volatility yearly60.86% Relative Volume232.87% Average Volume202.08 K
New High New Low

News

2020-06-04 18:42:27 | Is Bellerophon Therapeutics, Inc. BLPH A Good Stock To Buy?

2020-05-29 13:18:12 | Alan Fournier Adds 4 Stocks to Portfolio

2020-05-22 09:47:30 | Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares

2020-05-19 18:53:20 | 8 Biotechs Tapping Secondary Markets for $3 Billion

2020-05-19 07:00:10 | Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering

2020-05-18 16:03:15 | Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock

2020-05-12 10:09:02 | Company News for May 12, 2020

2020-05-11 16:01:10 | Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results

2020-05-11 08:30:10 | Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19

2020-05-04 08:30:10 | Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference

2020-04-17 12:19:00 | These experimental drugs may help keep COVID-19 patients off ventilators

2020-04-08 20:23:59 | Covid-19: Could Bellerphon Therapeutics’ INOpulse Help Address Hospital Ventilator Shortage?

2020-04-08 08:30:10 | Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19

2020-04-06 10:23:46 | Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

2020-04-01 13:06:11 | Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock

2020-03-31 08:30:10 | Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19

2020-03-30 09:57:55 | Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market

2020-03-30 08:00:10 | Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

2020-03-29 15:44:01 | Bellerophon Shares Jump On Covid-19 OK

2020-03-23 09:30:01 | Company News for Mar 23, 2020

2020-03-22 08:19:03 | 3 Coronavirus Stocks with Over 60% Upside

2020-03-20 08:30:10 | FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus

2020-03-10 08:30:10 | Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

2020-02-21 12:11:22 | The One Metric That Helps Me Find Stocks With The Greatest Potential

2020-02-19 10:32:03 | Company News for Feb 19, 2020

2020-02-19 09:21:02 | Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates

2020-02-19 07:21:54 | The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

2020-02-18 08:30:10 | Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

2020-02-07 12:00:10 | Bellerophon Announces 1-for-15 Reverse Stock Split

2019-12-20 16:18:28 | Is Bellerophon Therapeutics, Inc. BLPH Going to Burn These Hedge Funds?

2019-12-17 08:44:00 | Bellerophon stock is up 35% on hypertension trial data

2019-12-17 07:00:10 | Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2019-11-12 08:30:00 | Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2019-11-07 08:30:00 | Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019

2019-11-06 08:30:00 | Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results

2019-11-01 11:51:53 | Largest Insider Trades of the Week

2019-10-28 07:15:00 | BLPH: More Clinical Data Supports Utility of INOpulse, Near-Term Value-Inflection Opportunities Grow

2019-10-23 08:30:05 | Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

2019-10-23 07:54:59 | The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data

2019-10-20 08:08:45 | The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

2019-10-14 08:30:00 | Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

2019-09-16 08:30:00 | Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis

2019-09-04 08:30:00 | Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference

2019-08-08 12:57:41 | Bellerophon Therapeutics, Inc. NASDAQ:BLPH Insiders Increased Their Holdings

2019-08-08 08:30:00 | Bellerophon Provides Business Update and Reports Second Quarter 2019 Financial Results

2019-08-06 20:15:00 | BLPH: Zacks SCR Initiates Coverage of Bellerophon Therapeutics

2019-08-01 08:30:00 | Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2019-06-13 08:00:00 | Bellerophon to Present at the JMP Securities Life Sciences Conference

2019-05-22 08:30:00 | Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease

2019-05-21 08:30:00 | Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference